THELMA Therapeutics (KOSE:A015540) - Stock Price, News & Analysis

A015540 Stock Overview

THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. More details

A015540 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (₩4B)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months

Does not have meaningful revenue (₩7B)

THELMA Therapeutics Co., Ltd. Competitors

Wise birds

KOSDAQ:A273060

₩41.3b

Macromill Embrain

KOSDAQ:A169330

₩36.2b

eMnet

KOSDAQ:A123570

₩52.1b

NBT

KOSDAQ:A236810

₩54.7b

Price History & Performance

Summary of all time highs, changes and price drops for THELMA Therapeutics
Historical stock prices
Current Share Price	₩70.00
52 Week High	₩300.00
52 Week Low	₩55.00
Beta	0.26
11 Month Change	-98.91%
3 Month Change	-98.91%
1 Year Change	n/a
33 Year Change	-98.99%
5 Year Change	-99.05%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	A015540	KR Media	KR Market
7D	-6.7%	1.8%	2.9%
1Y	n/a	-19.0%	-2.8%

Return vs Industry: Insufficient data to determine how A015540 performed against the KR Media industry.

Return vs Market: Insufficient data to determine how A015540 performed against the KR Market.

Price Volatility

Is A015540's price volatile compared to industry and market?
A015540 volatility
A015540 Average Weekly Movement	35.9%
Media Industry Average Movement	5.4%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	11.5%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A015540's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine A015540's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	4	Lee Kyu	thelma.co.kr

THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. The company develops TLM-01, a non-alcoholic steatohepatitis drug; TLM-02, an antiviral agent for COVID-19; TLM-03/TLM-04, an anticancer drug for solid and blood cancer; and TLM-05, a liver cancer drug. It also offers radioembolization and brachytherapy devices for the cancer treatments.

THELMA Therapeutics Co., Ltd. Fundamentals Summary

How do THELMA Therapeutics's earnings and revenue compare to its market cap?
A015540 fundamental statistics
Market cap	₩4.37b
Earnings (TTM)	-₩3.36b
Revenue (TTM)	₩6.51b

0.7x

P/S Ratio

-1.3x

P/E Ratio

Is A015540 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A015540 income statement (TTM)
Revenue	₩6.51b
Cost of Revenue	₩6.45b
Gross Profit	₩52.97m
Other Expenses	₩3.42b
Earnings	-₩3.36b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-53.91
Gross Margin	0.81%
Net Profit Margin	-51.67%
Debt/Equity Ratio	10.7%

How did A015540 perform over the long term?

See historical performance and comparison

THELMA Therapeutics KOSE:A015540 Stock Report